Synopsis
Synopsis
0
CEP/COS
0
NDC API
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Kw 4354
2. Kw-4354
3. Oxatimide
4. R 35443
5. R35443
6. Tinset
1. 60607-34-3
2. Tinset
3. Celtect
4. Cobiona
5. Dasten
6. Kw-4354
7. 3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1h-benzimidazol-2-one
8. 1-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2h-benzimidazol-2-one
9. R-35443
10. R 35,443
11. 1-(3-(4-benzhydrylpiperazin-1-yl)propyl)-1h-benzo[d]imidazol-2(3h)-one
12. Oxatimide
13. Nsc-309710
14. 1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-2-benzimidazolinone
15. J31il9z2ee
16. 1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-2h-benzimidazol-2-one
17. Mls000028549
18. Oxatomidum
19. Oxatomida
20. Ncgc00015774-03
21. Smr000058301
22. 1-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-2-benzimidazolinone
23. Oxatomidum [inn-latin]
24. 2h-benzimidazol-2-one, 1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-
25. Dsstox_cid_25181
26. Dsstox_rid_80729
27. Dsstox_gsid_45181
28. Oxatomida [inn-spanish]
29. Mcn-jr 35443
30. R 35443
31. Celtect (tn)
32. Cas-60607-34-3
33. Einecs 262-320-9
34. Cbmicro_024634
35. Unii-j31il9z2ee
36. Brn 4724760
37. Oxatomide (jan/usan/inn)
38. 1-{3-[4-(diphenylmethyl)-1-piperazinyl]propyl}-1,3-dihydro-2h-benzimidazol-2-one
39. Oxatomide [usan:inn:ban:jan]
40. Oxatomide, >=99%
41. Oxatomide [inn]
42. Oxatomide [jan]
43. Oxatomide [mi]
44. Oxatomide [usan]
45. Lopac-o-9387
46. Oxatomide [mart.]
47. O 9387
48. Cid_4615
49. Oxatomide [who-dd]
50. Lopac0_000924
51. Oprea1_338592
52. Regid_for_cid_4615
53. Schembl28824
54. Chembl13828
55. Dtxsid4045181
56. Bdbm76863
57. Chebi:31943
58. Hms2089n07
59. Hms2231h12
60. Hms3372k08
61. Tox21_110219
62. Ccg-11811
63. Nsc309710
64. Nsc771641
65. Zinc19632896
66. Akos000507212
67. Tox21_110219_1
68. Ab04841
69. Db12877
70. Ks-1375
71. Nsc 309710
72. Nsc-771641
73. 2h-benzimidazol-2-one, 1,3-dihydro-1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-
74. Ncgc00015774-01
75. Ncgc00015774-02
76. Ncgc00015774-04
77. Ncgc00015774-05
78. Ncgc00015774-06
79. Ncgc00094235-01
80. Ncgc00094235-02
81. Bim-0024581.p001
82. Db-053668
83. Hy-123205
84. Cs-0081837
85. Eu-0100924
86. Ft-0630723
87. D01773
88. Ab01227629-02
89. 607o343
90. A832804
91. Sr-01000076051
92. Q2071515
93. Sr-01000076051-1
94. W-105243
95. 3-[3-(4-benzhydrylpiperazino)propyl]-1h-benzimidazol-2-one
96. 3-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1h-benzimidazol-2-one
97. 3-[3-[4-(diphenylmethyl)piperazin-1-yl]propyl]-1h-benzimidazol-2-one
98. 1-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1,3-dihydro-2h-benzimidazol-2-one
99. 1-{3-[4-(diphenylmethyl)-1-piperazinyl}-propyl}-1,3-dihydro-2h-benzimidazol-2-one
100. 1{-[4-(diphenylmethyl)-1-piperzinyl]propyl}-1,3-dihydro-2h-benzimidazol-2-one
Molecular Weight | 426.6 g/mol |
---|---|
Molecular Formula | C27H30N4O |
XLogP3 | 4.1 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 7 |
Exact Mass | 426.24196159 g/mol |
Monoisotopic Mass | 426.24196159 g/mol |
Topological Polar Surface Area | 38.8 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 575 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Asthmatic Agents
Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
R - Respiratory system
R06 - Antihistamines for systemic use
R06A - Antihistamines for systemic use
R06AE - Piperazine derivatives
R06AE06 - Oxatomide
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
ABOUT THIS PAGE
A Oxatomide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Oxatomide, including repackagers and relabelers. The FDA regulates Oxatomide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Oxatomide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Oxatomide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Oxatomide supplier is an individual or a company that provides Oxatomide active pharmaceutical ingredient (API) or Oxatomide finished formulations upon request. The Oxatomide suppliers may include Oxatomide API manufacturers, exporters, distributors and traders.
click here to find a list of Oxatomide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Oxatomide DMF (Drug Master File) is a document detailing the whole manufacturing process of Oxatomide active pharmaceutical ingredient (API) in detail. Different forms of Oxatomide DMFs exist exist since differing nations have different regulations, such as Oxatomide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Oxatomide DMF submitted to regulatory agencies in the US is known as a USDMF. Oxatomide USDMF includes data on Oxatomide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Oxatomide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Oxatomide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Oxatomide Drug Master File in Japan (Oxatomide JDMF) empowers Oxatomide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Oxatomide JDMF during the approval evaluation for pharmaceutical products. At the time of Oxatomide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Oxatomide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Oxatomide Drug Master File in Korea (Oxatomide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Oxatomide. The MFDS reviews the Oxatomide KDMF as part of the drug registration process and uses the information provided in the Oxatomide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Oxatomide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Oxatomide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Oxatomide suppliers with KDMF on PharmaCompass.
A Oxatomide written confirmation (Oxatomide WC) is an official document issued by a regulatory agency to a Oxatomide manufacturer, verifying that the manufacturing facility of a Oxatomide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Oxatomide APIs or Oxatomide finished pharmaceutical products to another nation, regulatory agencies frequently require a Oxatomide WC (written confirmation) as part of the regulatory process.
click here to find a list of Oxatomide suppliers with Written Confirmation (WC) on PharmaCompass.
Oxatomide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Oxatomide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Oxatomide GMP manufacturer or Oxatomide GMP API supplier for your needs.
A Oxatomide CoA (Certificate of Analysis) is a formal document that attests to Oxatomide's compliance with Oxatomide specifications and serves as a tool for batch-level quality control.
Oxatomide CoA mostly includes findings from lab analyses of a specific batch. For each Oxatomide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Oxatomide may be tested according to a variety of international standards, such as European Pharmacopoeia (Oxatomide EP), Oxatomide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Oxatomide USP).
LOOKING FOR A SUPPLIER?